Plain-English translation of NCT03461289 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Spinal muscular atrophy research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a gene replacement therapy designed to treat spinal muscular atrophy (SMA) type 1 in very young infants. The medication works by delivering a healthy copy of the survival motor neuron (SMN) gene into the body through a single IV infusion. Researchers studied whether this one-time treatment could help infants with this serious genetic condition that affects muscle strength and movement.
Spinal muscular atrophy type 1 is a severe genetic condition that progressively weakens muscles in infants, making it hard for them to breathe, swallow, and move. This trial was designed to test whether the medication could provide a new treatment option by replacing the faulty gene responsible for the disease, potentially slowing or stopping muscle weakness in affected infants.
Families went through a screening period to confirm their infant qualified for the trial. On Day 1, the infant was admitted to the hospital and received a single IV infusion of the medication, followed by 48 hours of close safety monitoring before being discharged. After that, families returned for regular outpatient visits over the next 18 months to track the infant's progress and check for any side effects.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Belgium
France
Italy